Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights

KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading

Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products

One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading

EB 148: KEI’s statement on WHO’s Global Observatory on Health R&D

On Friday, 22 January 2021, Knowledge Ecology International delivered the following remarks on WHO”s Global Observatory on Health R&D at the 148th session of WHO’s Executive Board. At meetings of WHO governing bodies, non-State actors are limited to one minute… Continue Reading

Letter from the People’s Vaccine Alliance and Health Action International to Dr. Tedros on C-TAP

On 21 January 2021 the People’s Vaccine Alliance and Health Action International (HAI) sent an open letter to Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), expressing concern about the lack of political support and reported progress… Continue Reading

WHO informal consultation (3 December 2020) addressed concerns on price transparency and shortages

On Monday, 11 January 2021, the secretariat of the World Health Organization (WHO) published an 18 page report on the Global strategy and plan of action on public health, innovation and intellectual property (EB148/10). The Director-General’s report contains a detailed… Continue Reading

$1.8 Billion Sanofi Vaccine Contract Contains International Reference Pricing Clause, Preserves Standard IP and Data Rights

The contract awarding Sanofi Pasteur (“Sanofi”) 1.8 billion U.S. taxpayers’ dollars for the development and manufacture of a COVID-19 vaccine was posted in the Department of Health and Human Services (HHS) Electronic Reading Room on November 30, 2020. Overall, the… Continue Reading

WHA73: Oral statement of Knowledge Ecology International – 11.9 – Global strategy and plan of action on public health, innovation and intellectual property

KEI is an accredited non-state actor at the World Health Organization (WHO). This was the oral statement we delivered during the resumed session of the WHA 73 in November 2020. Our statement focused on agenda item 11.9 – Global strategy… Continue Reading

$1 Billion Johnson & Johnson COVID-19 Contract Weakens IP and Data Protections for Taxpayers

On November 7, 2020, the Department of Health and Human Services (HHS) posted another COVID-19 vaccine contract: the $1 billion agreement between Janssen Pharmaceutical (a component of Johnson & Johnson (“J&J”)) and the U.S. government (through an intermediary called Advanced… Continue Reading